Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR.

Cell Signal

Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan 47392, Republic of Korea; Department of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan 47392, Republic of Korea. Electronic address:

Published: February 2017


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In this study, we presented the role of 14-3-3σ to activate CK2-Hsp90β-PXR-MDR1 pathway on rifampin and paclitaxel treated LS174T cells and in vivo LS174T cell-xenografted nude mouse model. Following several in vitro and in vivo experiments, rifampin and paclitaxel were found to be stimulated the CK2-Hsp90β-PXR-MDR1 pathway. Of the proteins in this pathway, Pregnane X receptor (PXR) is a representative transcription factor of multidrug resistance protein 1 (MDR1). We constructed FLAG-PXR-LS174T stable cell lines and discovered 22 proteins that interacted with PXR on rifampin treatment. Among them, Hsp90β and 14-3-3σ were isolated for further study. Both the proteins were found to be localized in cytoplasm on rifampin treatment by using confocal microscopy. On the other hand, PXR was found to be localized in nucleus after rifampin and paclitaxel treatment by using cell fractionation assay. In Western blot analysis, rifampin did not influence the expression of 14-3-3σ protein. Transient transfection of 14-3-3σ into LS174T cells induced overexpression of PXR; however, P-glycoprotein (P-gp) was not changed significantly. P-gp overexpression was induced only when 14-3-3σ transfected LS174T cells were treated with rifampin and paclitaxel, whereas 14-3-3σ inhibition by nonpeptidic inhibitor, BV02 and 14-3-3σ siRNA reduced rifampin induced PXR and P-gp expression. Cell survival rates were much higher at 14-3-3σ-LS174T stable cell lines than LS174T cells following paclitaxel and vincristine treatment. This data indicates that 14-3-3σ contributes to P-gp overexpression through interaction with PXR with rifampin and paclitaxel treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellsig.2017.01.001DOI Listing

Publication Analysis

Top Keywords

rifampin paclitaxel
24
ls174t cells
16
rifampin
10
interaction pxr
8
14-3-3σ
8
ck2-hsp90β-pxr-mdr1 pathway
8
stable cell
8
cell lines
8
pxr rifampin
8
rifampin treatment
8

Similar Publications

Assessment of polymeric mucin-drug interactions.

PLoS One

June 2024

Wellcome Centre for Cell-Matrix Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom.

Mucosal-delivered drugs have to pass through the mucus layer before absorption through the epithelial cell membrane. Although there has been increasing interest in polymeric mucins, a major structural component of mucus, potentially acting as important physiological regulators of mucosal drug absorption, there are no reports that have systematically evaluated the interaction between mucins and drugs. In this study, we assessed the potential interaction between human polymeric mucins (MUC2, MUC5B, and MUC5AC) and various drugs with different chemical profiles by simple centrifugal method and fluorescence analysis.

View Article and Find Full Text PDF

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug-Drug Interaction Liabilities.

Pharmaceutics

September 2022

Division of Pharmaceutics and Pharmacology, College of Pharmacy & Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.

In recent years, various endogenous compounds have been proposed as putative biomarkers for the hepatic uptake transporters OATP1B1 and OATP1B3 that have the potential to predict transporter-mediated drug-drug interactions (DDIs). However, these compounds have often been identified from top-down strategies and have not been fully utilized as a substitute for traditional DDI studies. In an attempt to eliminate observer bias in biomarker selection, we applied a bottom-up, untargeted metabolomics screening approach in mice and found that plasma levels of the conjugated bile acid chenodeoxycholate-24-glucuronide (CDCA-24G) are particularly sensitive to deletion of the orthologous murine transporter Oatp1b2 (31-fold increase vs.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists studied a new cancer-fighting drug called 5a to see how it affects a protein that can make drugs less effective, known as P-glycoprotein (P-gp).
  • They used special lab techniques to find out that 5a helps reduce the amount and activity of P-gp in cancer cells.
  • The findings suggest that using 5a with other cancer drugs could help overcome problems when cancer cells become resistant to treatment.
View Article and Find Full Text PDF

Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.

J Ethnopharmacol

April 2018

Phytotherapy Research Lab., Medicinal & Aromatic Plant Division, Regional Plant Resource Centre, Forest & Environment Department, Govt. of Odisha, Nayapalli, Bhubaneswar 751015, India.

Article Synopsis
  • Alzheimer's disease (AD) is a complex neurodegenerative disorder that affects memory and cognitive functions, with existing FDA-approved treatments only providing symptomatic relief rather than a cure.
  • Various traditional and ethnobotanical sources, including plants used in Indian, Chinese, and European medicine, show promise in developing new AD therapies, while the overexploitation of specific medicinal plants has inspired the creation of synthetic drugs like rivastigmine and new prodrugs.
  • The article emphasizes the need for a shift from a "one-molecule-one-target" approach to a "combination-drugs-multi-targets" strategy that addresses the multiple underlying factors of AD, along with exploring various biological sources for potential therapeutic agents.
View Article and Find Full Text PDF

MDR1 is highly expressed in MDR A2780DX5 ovarian cancer cells, MDR SGC7901R gastric cancer cells and recurrent tumours. It pumps cytoplasmic agents out of cells, leading to decreased drug accumulation in cells and making cancer cells susceptible to multidrug resistance. Here, we identified that miR-495 was predicted to target ABCB1, which encodes protein MDR1.

View Article and Find Full Text PDF